Omniab, Inc. · NASDAQ:OABI
Omniab — Stifel Healthcare Conference 2022
27 slides from Omniab's conference presentation, Nov 15, 2022
Slide 1: OmniAb, Inc. Stifel Healthcare Conference
1 OmniAb, Inc. Nasdaq: OABI Stifel Healthcare Conference New York, NY November 15-16, 2022
Slide 2: Disclaimer
2 Disclaimer We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, expected cash runway, business stra
Slide 3: OmniAb, Inc.
3 OmniAb, Inc. OUR BUSINESS MODEL IS FOCUSED ON LICENSING OUR PROPRIETARY DISCOVERY TECHNOLOGY ONE OF THE LARGEST GREENFIELDS IN THE PHARMA INDUSTRY $236 BILLION TOTAL ADDRESSABLE MARKET FOR ANTIBODIES BY 2025 LEADING AND PROVEN GLOBALLY-RECOGNIZED TECHNOLOGY SCIENCE AND TEAM GROWING ROSTER OF PARTN
Slide 4: Mission
Our mission is to enable the rapid Mission development of innovative therapeutics by pushing the frontiers of drug discovery technologies.
Slide 5: The OmniAb Platform
5 The OmniAb Platform LICENSES TO OUR TECHNOLOGY PLATFORM ARE STRUCTURED TO ALIGN ECONOMIC AND SCIENTIFIC INTERESTS WITH OUR PARTNERS Create Diverse Screen Antibody Identify the Antibody Pools Candidates Right Antibody Create Diverse Pools of High-Quality Screen Millions of Cells to Find Further Cha
Slide 6: Antibodies and Industry Demand
6 Antibodies and Industry Demand HIGHER SUCCESS RATES FOR ANTIBODY MEDICINES DRIVE OUR INDUSTRY’S NEED FOR DISCOVERY TECHNOLOGY Acceleration of Regulatory Increasing Antibody Market Approvals (FDA and EMA) • $236B in antibody sales by 2025 (up from ~$212B in 2021) 70 • 49 blockbuster antibodies in 2
Slide 7: The OmniAb Platform
7 The OmniAb Platform Create Diverse Screen Antibody Identify the Antibody Pools Candidates Right Antibody Create Diverse Pools of High-Quality Screen Millions of Cells to Find Further Characterize, Select & Naturally-Optimized Antibodies Potential Therapeutic Candidates Optimize the Right Antibody
Slide 8: What is Biological Intelligence™?
8 What is Biological Intelligence™? • We believe that antibodies generated in vivo are superior to ones from other sources because they are naturally optimized through an iterative process that preferentially selects for antibodies with excellent specificity and developability profiles • The ability
Slide 9: The OmniAb Platform
9 The OmniAb Platform Create Diverse Screen Antibody Identify the Antibody Pools Candidates Right Antibody Antibody Generation Technologies We believe generating large and diverse pools of high-quality antibodies increases the likelihood of Computational discovering the antibody with the Antigen Des
Slide 10: OmniChicken
10 OmniChicken POWERED BY EVOLUTION
Slide 11: Antibody Repertoires
11 Antibody Repertoires NUMEROUS OPTIONS AVAILABLE TO ADDRESS DIVERSE PARTNER OBJECTIVES Structural and Benefits for therapeutics Host V genes immunological features discovery and development • Full human V gene diversity • Diverse V gene usage and mixed • Widely accessible and flexible workflows •
Slide 12: Screening Platforms
12 Screening Platforms Create Diverse Screen Antibody Identify the Antibody Pools Candidates Right Antibody Immunization Isolate B-cells Expression Validation Sequence Bioinformatics Hybridoma Workflow Fusion Screen enrichment Single-cell B-cell optional NGS Workflow Our powerful single B-cell scree
Slide 13: The OmniAb Platform
13 The OmniAb Platform Create Diverse Screen Antibody Identify the Antibody Pools Candidates Right Antibody Our discovery teams are flexibly positioned to work closely with partners to identify the right antibody • Data from multi-parameter screening and performance assays used in combination with b
Slide 14: Ion Channels and Transporters
14 Ion Channels and Transporters WE HAVE EXTENSIVE BIOLOGICAL CAPABILITIES FOR ION CHANNELS AND TRANSPORTERS Proprietary assays leveraged for Proprietary cell lines enable discovery and characterization of high-speed antigen production antibodies Create Diverse Screen Antibody Identify the Antibody
Slide 15: Growth of Partner Programs
15 Growth of Partner Programs PROGRESSION AND PERFORMANCE IN PROGRAMS BY STAGE OF DEVELOPMENT 282 as of 09/30/22(2) Phase 3: 2 21 as of 2016(1) Phase 2: 2 Phase 1: 18 Approved: 3 Preclinical: 12 Preclinical: 1 Discovery: 20 Substantial progress in all phases, increase in discovery programs expected
Slide 16: Diverse Drug Formats and Modalities
16 Diverse Drug Formats and Modalities PRECLINICAL AND CLINICAL OMNIAB MOLECULES FORMATS MODALITIES IgG Duobody® ADAPTIR™ ADC (IgG4 exchange) scFv-Fc-scFv 6% Bispecific Monoclonal IgG (incl. T cell engager) 57% 37% Fab-Heavy chain IgG-scFv Antibody-Drug (Knob-in-hole) Conjugate Variety in the format
Slide 17: Select OmniAb Partners
17 Select OmniAb Partners >65 COMPANIES CURRENTLY HAVE ACCESS TO OMNIAB ANTIBODIES
Slide 18: Key Performance Indicators
18 Key Performance Indicators TECHNOLOGY AND BUSINESS MODEL ARE HIGHLY SCALABLE Number of Active Number of Active Number of Active Clinical Programs and Partners Programs Approved Products • Strong annual growth in key 25 performance indicators continues 70 300 ‒ Active Partners:(1) >30% CAGR 60 250
Slide 19: Approved and Clinical-Stage Partner Pipeline
19 Approved and Clinical-Stage Partner Pipeline NOW WITH THREE APPROVED PRODUCTS AND 22 ACTIVE CLINICAL-STAGE ANTIBODIES Partner Program Source Animal Therapy Area Target Preclinical Phase 1 Phase 2 Phase 3 Registration Approved Zimberelimab OmniRat Oncology PD-1 Sugemalimab OmniRat Oncology PD-L1 T
Slide 20: Intellectual Property Advantage
20 Intellectual Property Advantage PARTNERS FILING PATENTS ON OMNIAB-DERIVED ANTIBODIES CAN CREATE DIVERSE AND DURABLE ROYALTY STREAMS AND A LENGTHY IP TAIL Over 300 patents issued worldwide Antibody Patent Applications Filed by Partners 70 • We maintain a broad intellectual property estate with mul
Slide 21: Business Model
21 Business Model OUR AGREEMENTS ARE STRUCTURED TO ALIGN ECONOMIC AND SCIENTIFIC INTERESTS WITH OUR PARTNERS License partnerships designed to include: • Upfront and collaboration/access fees • Milestones • Royalties on commercial sales
Slide 22: Illustrative Antibody Deal Structure
22 Illustrative Antibody Deal Structure Profile A Profile B Potential IP Extension Potential IP Extension Year 0 5 10 15 20 25 Year 0 5 10 15 20 25 Collaboration/ Clinical & Regulatory Royalties: Collaboration/ Clinical & Regulatory Royalties: Access Fees: Milestones: ~Low Single Access Fees: Milest
Slide 23: Cash Position Provides Long Operational Runway
23 Cash Position Provides Long Operational Runway ($ millions) Gross Cash Proceeds $130 Underwriting/Transaction/Other Fees ~$35 Net Cash ~$95 Shares Outstanding 114.8 million Shares Outstanding includes earnout shares, but excludes OmniAb options, RSUs, PSUs and APAC warrants BUSINESS IS CLOSE TO B
Slide 24: Management Board of Directors
24 Management Matt Foehr Kurt Gustafson Charles Berkman Bill Harriman, PhD Christel Iffland, PhD Marie-Cecile Doug Krafte, PhD Chief Executive Officer Chief Financial Officer Chief Legal Officer SVP, Antibody Discovery SVP, Antibody Technologies Van De Lavoir, PhD, DVM SVP, Ion Channels Board Member
Slide 25: Our Key Areas of Focus Going Forward
25 Our Key Areas of Focus Going Forward WE BELIEVE WE ARE WELL-POSITIONED FOR FUTURE GROWTH WHILE WE MAKE AN ENDURING AND SIGNIFICANT IMPACT ON THE INDUSTRY AND GLOBAL HUMAN HEALTH WE LEVERAGE A HIGHLY Partnered Pipeline Development, Expansion and Advancement SCALABLE BUSINESS WHERE Continued Workfl
Slide 26: OmniAb, Inc. Summary
26 OmniAb, Inc. Summary • Demand for antibody-based approaches drives the industry’s need for cutting-edge discovery technologies • We maintain a highly scalable business where investments in and extensions of our differentiated technology are informed by a deep portfolio of partnerships • Our partn
Slide 27: For more information, please visit www.omniab.com
27 For more information, please visit www.omniab.com